Edition:
United States

Gemphire Therapeutics Inc (GEMP.OQ)

GEMP.OQ on NASDAQ Stock Exchange Global Market

8.01USD
14 Dec 2017
Change (% chg)

$-0.26 (-3.14%)
Prev Close
$8.27
Open
$8.20
Day's High
$8.20
Day's Low
$7.92
Volume
9,527
Avg. Vol
22,593
52-wk High
$21.59
52-wk Low
$7.22

Chart for

About

Gemphire Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to... (more)

Overall

Beta: --
Market Cap(Mil.): $85.17
Shares Outstanding(Mil.): 10.63
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 196.13 16.04
EPS (TTM): -- -- --
ROI: -- -11.69 35.70
ROE: -- -36.44 15.40

BRIEF-Gemphire Therapeutics reports qtrly loss of $0.82‍​/shr

* Gemphire Therapeutics Inc qtrly loss per share $0.82‍​ Source: (http://bit.ly/2iaJuNF) Further company coverage:

Nov 13 2017

BRIEF-Gemphire announces plans to advance gemcabene into phase 3 clinical development

* Gemphire announces plans to advance gemcabene into phase 3 clinical development

Sep 19 2017

BRIEF-Gemphire Therapeutics Inc files mixed shelf of up to $175 million - SEC filing ‍​

* Gemphire therapeutics inc files mixed shelf of up to $175 million - SEC filing ‍​ Source text: (http://bit.ly/2vRDX2x) Further company coverage:

Sep 01 2017

BRIEF-Gemphire Therapeutics Inc posts Q2 net loss $0.99/shr

* Gemphire announces second quarter 2017 financial results and provides corporate update

Aug 14 2017

BRIEF-Gemphire announces top-line data from royal-1 phase 2b clinical trial in hypercholesterolemic patients

* Gemphire announces top-line data from royal-1 phase 2b clinical trial in hypercholesterolemic patients

Aug 07 2017

BRIEF-Gemphire enters into $15 mln term loan agreement with Silicon Valley Bank

* Gemphire enters into $15 million term loan agreement with silicon valley bank

Jul 25 2017

Earnings vs. Estimates